Sensei Biotherapeutics Stock Performance

SNSE Stock  USD 9.09  0.25  2.83%   
On a scale of 0 to 100, Sensei Biotherapeutics holds a performance score of 4. The entity has a beta of 1.36, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sensei Biotherapeutics will likely underperform. Please check Sensei Biotherapeutics' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Sensei Biotherapeutics' existing price patterns will revert.

Risk-Adjusted Performance

Soft

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Sensei Biotherapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of rather abnormal basic indicators, Sensei Biotherapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

Five Day Return
4
Year To Date Return
(5.80)
Ten Year Return
(97.60)
All Time Return
(97.60)
Last Split Factor
1:20
Last Split Date
2025-06-17
1
Why Sensei Biotherapeutics Inc. stock attracts HNW investors - Share Buyback Verified Entry Point Detection - newser.com
11/18/2025
2
Insider Trading
11/24/2025
3
Is Sensei Biotherapeutics Inc. stock vulnerable to regulatory risks - Treasury Yields Comprehensive Market Scan Reports - B NI V
11/26/2025
4
Disposition of 2843 shares by Van Der Horst Edward of Sensei Biotherapeutics at 0.79 subject to Rule 16b-3
11/28/2025
5
Disposition of 5000 shares by Peyer James of Sensei Biotherapeutics at 9.06 subject to Rule 16b-3
12/04/2025
6
Disposition of 3105 shares by Peyer James of Sensei Biotherapeutics at 8.59 subject to Rule 16b-3
12/08/2025
7
Disposition of 5 shares by Peyer James of Sensei Biotherapeutics at 6.4 subject to Rule 16b-3
12/09/2025
8
What Sparked Sensei Biotherapeutics Stocks Nearly 63 percent AfterHours Jump - Sahm
12/11/2025
9
Sensei Biotherapeutics updates executive retention and compensation agreements - MSN
12/22/2025
10
What Makes Sensei Biotherapeutics a New Buy Stock - MSN
12/29/2025
11
What is the Moat Score of Sensei Biotherapeutics Inc. - Earnings Risk Summary Weekly High Return Stock Forecasts - mfd.ru
02/13/2026
Begin Period Cash Flow13 M
Total Cashflows From Investing Activities22.4 M

Sensei Biotherapeutics Relative Risk vs. Return Landscape

If you would invest  814.00  in Sensei Biotherapeutics on November 17, 2025 and sell it today you would earn a total of  95.00  from holding Sensei Biotherapeutics or generate 11.67% return on investment over 90 days. Sensei Biotherapeutics is currently generating 0.4153% in daily expected returns and assumes 7.0955% risk (volatility on return distribution) over the 90 days horizon. In different words, 63% of stocks are less volatile than Sensei, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Sensei Biotherapeutics is expected to generate 9.29 times more return on investment than the market. However, the company is 9.29 times more volatile than its market benchmark. It trades about 0.06 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of risk.

Sensei Biotherapeutics Target Price Odds to finish over Current Price

The tendency of Sensei Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 9.09 90 days 9.09 
about 62.45
Based on a normal probability distribution, the odds of Sensei Biotherapeutics to move above the current price in 90 days from now is about 62.45 (This Sensei Biotherapeutics probability density function shows the probability of Sensei Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.36 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Sensei Biotherapeutics will likely underperform. Additionally Sensei Biotherapeutics has an alpha of 0.0693, implying that it can generate a 0.0693 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Sensei Biotherapeutics Price Density   
       Price  

Predictive Modules for Sensei Biotherapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Sensei Biotherapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Sensei Biotherapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
2.009.1016.20
Details
Intrinsic
Valuation
LowRealHigh
7.5714.6721.77
Details
2 Analysts
Consensus
LowTargetHigh
29.5832.5036.08
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-4.54-4.54-4.54
Details

Sensei Biotherapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Sensei Biotherapeutics is not an exception. The market had few large corrections towards the Sensei Biotherapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Sensei Biotherapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Sensei Biotherapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.07
β
Beta against Dow Jones1.36
σ
Overall volatility
1.04
Ir
Information ratio 0.01

Sensei Biotherapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Sensei Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Sensei Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Sensei Biotherapeutics had very high historical volatility over the last 90 days
Sensei Biotherapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (30.16 M) with profit before overhead, payroll, taxes, and interest of 0.
Sensei Biotherapeutics currently holds about 123.71 M in cash with (24.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.03.
Sensei Biotherapeutics has a poor financial position based on the latest SEC disclosures
Roughly 32.0% of the company outstanding shares are owned by corporate insiders
Latest headline from prnewswire.com: Evogene Announces a Warrant Inducement Transaction for Approximately 3.4 Million of Gross Proceeds

Sensei Biotherapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Sensei Stock often depends not only on the future outlook of the current and potential Sensei Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Sensei Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding25.1 M
Cash And Short Term Investments41.3 M

Sensei Biotherapeutics Fundamentals Growth

Sensei Stock prices reflect investors' perceptions of the future prospects and financial health of Sensei Biotherapeutics, and Sensei Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sensei Stock performance.

About Sensei Biotherapeutics Performance

By analyzing Sensei Biotherapeutics' fundamental ratios, stakeholders can gain valuable insights into Sensei Biotherapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Sensei Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sensei Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.60)(0.63)
Return On Capital Employed(0.91)(0.87)
Return On Assets(0.60)(0.63)
Return On Equity(0.90)(0.86)

Things to note about Sensei Biotherapeutics performance evaluation

Checking the ongoing alerts about Sensei Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sensei Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Sensei Biotherapeutics had very high historical volatility over the last 90 days
Sensei Biotherapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (30.16 M) with profit before overhead, payroll, taxes, and interest of 0.
Sensei Biotherapeutics currently holds about 123.71 M in cash with (24.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.03.
Sensei Biotherapeutics has a poor financial position based on the latest SEC disclosures
Roughly 32.0% of the company outstanding shares are owned by corporate insiders
Latest headline from prnewswire.com: Evogene Announces a Warrant Inducement Transaction for Approximately 3.4 Million of Gross Proceeds
Evaluating Sensei Biotherapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Sensei Biotherapeutics' stock performance include:
  • Analyzing Sensei Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sensei Biotherapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Sensei Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Sensei Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sensei Biotherapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Sensei Biotherapeutics' stock. These opinions can provide insight into Sensei Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Sensei Biotherapeutics' stock performance is not an exact science, and many factors can impact Sensei Biotherapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Sensei Stock analysis

When running Sensei Biotherapeutics' price analysis, check to measure Sensei Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sensei Biotherapeutics is operating at the current time. Most of Sensei Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Sensei Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sensei Biotherapeutics' price. Additionally, you may evaluate how the addition of Sensei Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Content Syndication
Quickly integrate customizable finance content to your own investment portal